Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Scott H. Davis who wrote (33)	3/1/1999 8:25:00 PM
From: BRAVEHEART	Read Replies (1) \| Respond to of 52153

As NXTR & GILD merge that which we seek spews forth a list of those like minded companies which will trod forth among the fallen and out of favor and stand out as those most worthy of growth within the sector at large. Companies presenting at the San Diego Stocks Forum are Anesta, AVI BioPharma, CoCensys, CombiChem, Corvas, Collateral Therapeutics, Interpore, ISIS, SunPharm, Trega BioSciences and Vical. Up to 12 companies may present. Companies presenting at the Sixth SF Bay Biotech Stocks Forum are: Advanced Tissues Sciences, Anesta, Aradigm, Cor Therapeutics, Genentech, Geron, Inhale Therapeutics, MGI Pharma., Microcide, NeoTherapeutics, NPS Pharma, Sugen, SuperGen and ViroPharma. Up to 16 companies may present. The seven companies presenting at the Atlanta Healthcare Stocks Forum are: GeneLogic, Collateral Therapeutics, Merit Medical Systems, SpectRx, SunPharma, CytRx and CoCensys. biz.yahoo.com The challenge. Which three of these many companies are most undervalued from as many approaches as we can apply. CASH per share. Near term events. Technically poised to take off. Lacking upside resistance ( Warrants etc ) and downside incentives ( Convertibles ). Absent huge short positions for whatever conventional reasons. Etc Etc Etc. PS: It is rumored that SCIO will receive approval in the next several weeks. How about a quickie analysis. What exactly is the market potential to SCIOS. I believe SCIO is undervalued based on approval. What do you think? Is the product likely to have rapid penetration. SCIOS is my selection for a somewhat out of favor issue which is undervalued based upon my expectation of approval. BEST WISHES JEFFREY